Apellis Pharmaceuticals, Inc. (APLS) Dividend History

Company News

• Comprehensive Age-related Macular Degeneration Market Analysis: Trends and Developments Across All Types

  The age-related macular degeneration (AMD) market is expected to grow due to the launch of new therapies and increased healthcare spending. Dry AMD and wet AMD are the two main types, with new treatments in development for both.

  GlobeNewswire Inc.

  Featured Companies: CLSD
• Why Apellis Pharmaceuticals Wilted on Wednesday

  Apellis Pharmaceuticals reported a Q1 revenue decline and wider net loss, missing analyst expectations. However, the company continues to develop its drugs Syfovre and Empaveli for new indications, with an FDA decision on Empaveli expected in July.

  The Motley Fool
• Apellis (APLS) Falls on Second Negative CHMP Opinion for GA Drug

  Apellis (APLS) declines as CHMP issues a second negative opinion for the approval of intravitreal pegcetacoplan to treat GA in the EU. The company plans to seek re-examination of the same.

  Zacks Investment Research

  Featured Companies: ALXO ANVS CGEN
• What Analysts Are Saying About Apellis Pharmaceuticals Stock

  Throughout the last three months, 14 analysts have evaluated Apellis Pharmaceuticals (NASDAQ:APLS), offering a diverse set of opinions from bullish to bearish. The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 9 1 4 0 0 Last 30D 0 1 0 0 0 1M Ago 0 0 1 0 0 2M Ago 5 0 2 0 0 3M Ago 4 0 1 0 0 Insights from analysts' 12-month price targets are revealed, presenting an average target of $76.5, a high estimate of $100.00, and a low estimate of $46.00. This current average has decreased by 3.65% from the previous average price target of $79.40. Decoding Analyst Ratings: A Detailed Look The standing of Apellis Pharmaceuticals among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Colleen Kusy Baird Maintains Outperform $100.00 $100.00 Biren Amin Piper Sandler Announces Neutral $46.00 - Douglas Tsao HC Wainwright & Co. Maintains Buy $92.00 $92.00 Derek Archila Wells Fargo Lowers Equal-Weight $48.00 $57.00 Joseph Stringer Needham Maintains Buy $85.00 $85.00 Yigal Nochomovitz Citigroup Lowers Buy $60.00 $67.00 Douglas Tsao HC Wainwright & Co. Maintains Buy $92.00 - Eliana Merle UBS Lowers Buy $85.00 $89.00 Graig Suvannavejh Mizuho Lowers Neutral $52.00 $60.00 Douglas Tsao HC Wainwright & Co. Maintains Buy $92.00 $92.00 Joseph Stringer Needham Maintains Buy $85.00 $85.00 Laura Chico Wedbush Lowers Neutral $57.00 $67.00 Douglas Tsao HC Wainwright & Co. Maintains Buy $92.00 - Joseph Stringer Needham Maintains Buy $85.00 - Key Insights: Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or ...Full story available on Benzinga.com

  Benzinga
• Many Layoffs Already Announced In 2024, Why? AI That's Why

  Several successful companies have announced layoffs. Learn more about the layoffs and read why excessive job reductions could impact overall job growth.

  Seeking Alpha

  Featured Companies: AMZN BA BLK C META U